KEYTRUDA plus LENVIMA met the trial’s primary endpoint of progression-free survival

▴ KEYTRUDA plus LENVIMA met the trial’s primary endpoint of progression-free survival
LENVIMA plus everolimus were evaluated versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma

Merck, known as MSD outside the United States and Canada, and Eisai today announced new investigational data demonstrating positive top-line results from the pivotal Phase 3 KEYNOTE-581/CLEAR trial (Study 307). In the trial, the combinations of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, and LENVIMA plus everolimus were evaluated versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). KEYTRUDA plus LENVIMA met the trial’s primary endpoint of progression-free survival (PFS) and its key secondary endpoints of overall survival (OS) and objective response rate (ORR), demonstrating a statistically significant and clinically meaningful improvement in PFS, OS and ORR versus sunitinib in the intention-to-treat (ITT) study population. LENVIMA plus everolimus also met the trial’s primary endpoint of PFS and a key secondary endpoint of ORR, demonstrating a statistically significant and clinically meaningful improvement in PFS and ORR versus sunitinib in the ITT study population. The ITT population included patients across all Memorial Sloan Kettering Cancer Center (MSKCC) risk groups (favorable, intermediate and poor). The safety profiles of both KEYTRUDA plus LENVIMA and LENVIMA plus everolimus were consistent with previously reported studies. Merck and Eisai will discuss these data with regulatory authorities worldwide, with the intent to submit marketing authorization applications based on these results, which will be presented at an upcoming medical meeting.

“The results for KEYTRUDA plus LENVIMA versus sunitinib, which showed a statistically significant improvement in progression-free survival, overall survival and objective response rate, build on the growing scientific evidence that supports the investigation of KEYTRUDA-based combinations for the first-line treatment of advanced renal cell carcinoma,” said Dr. Gregory Lubiniecki, Associate Vice President, Oncology Clinical Research, Merck Research Laboratories. “Merck and Eisai are committed to working together to continue to explore the potential of the KEYTRUDA plus LENVIMA combination, particularly in areas of great unmet need such as renal cell carcinoma.”

“The results from KEYNOTE-581/CLEAR (Study 307) support the potential use of KEYTRUDA plus LENVIMA for the first-line treatment of advanced RCC. These data also support the potential first-line use of LENVIMA plus everolimus, which is already approved in advanced RCC following prior antiangiogenic therapy,” said Dr. Takashi Owa, Vice President, Chief Medicine Creation and Chief Discovery Officer, Oncology Business Group at Eisai. “These findings energize our efforts as we continue to advance our understanding and address the unmet needs of patients with difficult-to-treat cancers.”

Merck and Eisai are continuing to study the KEYTRUDA plus LENVIMA combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program across 19 trials in 13 different tumor types (endometrial carcinoma, hepatocellular carcinoma, melanoma, non-small cell lung cancer, RCC, squamous cell carcinoma of the head and neck, urothelial cancer, biliary tract cancer, colorectal cancer, gastric cancer, glioblastoma, ovarian cancer and triple-negative breast cancer).

Tags : #LatestPharmaNewsNov10 #LatestMerckNewsNov10 #TreatmentforAdvancedRenalCellCarcinoma #TreatmentForRenalCellCarnicoma

Related Stories

11 Nov

Historic Breakthrough: FDA Grants Accelerated Approval for Valneva’s Ixchiq - The First Chikungunya Vaccine

As the vaccine moves towards global markets, its impact on public health is poised to be substantial. The ongoing commitment to safety studies and pediatric evaluations reflects a dedication to comprehensive healthcare solutions. The pharmaceutical landscape is witnessing a transformative moment, and Ixchiq stands at the forefront of this medical breakthrough.

View
23 Oct

Indian Medtech Startup Sigtuple Receives U.S. FDA approval; becomes India's 1st company in this space to earn the clearance

For all haematological disorders like blood cancers, infections, anaemia & allergies, the microscopic examination of the peripheral blood smear (PBS) is the gold standard test, but microscopy today is predominantly a manual process - necessitating a highly skilled pathologist to be present on-site.

View
23 Sep

EQUIPPP welcomes Mr. Guru R. Sowle as an Advisor

This addition to EQUIPPP’s team is in alignment with realizing the MOU with BSE to fuel the growth of the Social Stock Exchange, a groundbreaking initiative empowering millions of non-profit organizations and social enterprises.

View
14 Sep

Seeking Justice: The Tragic Case of Jaahnavi Kandula and the inhumanity of US police

Jaahnavi's life ended tragically in a police car collision during her Master's pursuit. A detective's callous 'jokes' about her death emphasize the need for empathy and accountability in law enforcement.

View
26 Feb

Chronic Disease Management with USA’s Biofourmis

CDC estimates that 6 in 10 American adults have 1 chronic disease whereas 4 in 10 suffer from 2 or more chronic diseases. Learn how Biofourmis is changing this.

View
10 Feb

WHO requires $23 billion to end COVID pandemic

In an effort to end the COVID-19 pandemic the World Health Organisation (WHO) has asked the 55 wealthiest countries to raise $23 billion in funding.

View
13 Jan

Reliance Global Group acquires Medigap Health Insurance

The Reliance Global Group announced the complete acquisition of Medigap Health Insurance Co.

View
21 Jun

CNN analysis: Where vaccination is up, Covid-19 cases are down

CNN research shows vaccination is bringing down new Covid cases

View
28 Apr

Moderna announces agreement with Sanofi for manufacturing of the Moderna COVID-19 Vaccine in the U.S.

Moderna and Sanofi collaborate for covid vaccine manufacturing

View
05 Mar

Detroit mayor declines Johnson & Johnson allotment, saying the other vaccines are better

Detroit providers have administered 101,636 total Covid-19 vaccine doses, with 55,121 future doses already scheduled, according to the city's Covid-19 dashboard.

View

-Advertisements-




Trending Now

Teenagers Are Losing Friends While Chasing Perfection: Here’s WhyMarch 13, 2025
Your Desk Job is Destroying Your Mind: Here’s How to Fight BackMarch 13, 2025
Wow! Momo Disrupts FMCG Cup Noodles Market with 'Desi-Asian Flavours' – A First in IndiaMarch 13, 2025
How India’s Kidney Health Crisis is Growing UnnoticedMarch 13, 2025
Stuck Between the Snooze Button and the Hustle: Entrepreneurs Struggle to Get Quality SleepMarch 13, 2025
Can Coffee Keep You Steady on Your Feet? New Study Reveals the TruthMarch 13, 2025
NephroPlus Sets Guinness World Record & India Book of Records Title for Largest Kidney Health Screening DriveMarch 12, 2025
India Choosing to Eat Healthy; Order Volumes Up by 60% for Nutritional ProductsMarch 12, 2025
Amrita students win first prize at DecodeX 2025 hackathonMarch 12, 2025
Why Millions Are Losing Their Sight to Glaucoma And How You Can Prevent ItMarch 12, 2025
Çelebi India Ranks 3rd Worldwide in Ground Handling Performance for Turkish CargoMarch 12, 2025
Advancing Road Safety Through Clear Vision: VARS 4.0 Sets Bold AgendaMarch 12, 2025
The Deadly Cost of the “Perfect Body”: When Diet Trends Turn FatalMarch 12, 2025
Lighthouse Canton’s LC GenInnov Global Innovation Fund Secures Investment from Kotak Mahindra Asset ManagementMarch 11, 2025
TTK Prestige Revolutionizes Cooking with Innovative AirFlip Two-in-One Air Fryer and GrillMarch 11, 2025
Rewriting Immunology: The Discovery That Could Replace Traditional AntibioticsMarch 11, 2025
Is Your Cooking Oil Poisoning You? The Truth About Seed OilsMarch 11, 2025
Think Before You Bite: How Fatty Foods Can Trigger Brain Damage in Just 3 DaysMarch 11, 2025
Ditch the Pills: The Secret to Beating Insomnia is in Your WorkoutMarch 11, 2025
The University of Tasmania invites applications for Master of Public HealthMarch 11, 2025